Track topics on Twitter Track topics that are important to you
The FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread. Approval of the drug, which J&J will market under the brand name Erleada...
Original Article: J&J gets quick approval for new next-gen prostate cancer drugNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...